HERAN Partners is pleased to announce its investment in Hypervision Surgical, a London-based venture which aims to revolutionise the outcomes of surgical interventions by augmenting a surgeon’s ability to assess the status of tissue, to distinguish between different tissue types, and to discriminate healthy from unhealthy tissue. This investment endorses HERAN’s European expansion and broadening of the syndication partner network.
Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising GBP 6,5M. By harnessing AI and clinical edge computing, this King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.
"We are incredibly excited about the transformative potential of our Hyperspectral Intelligence platform," said Michael Ebner, CEO and co-founder of Hypervision Surgical. "Imagine a complex tumour surgery where surgeons can rely on precise measurements and tissue property information to distinguish between healthy and unhealthy tissue. Our technology makes the invisible visible, empowering surgeons to make confident decisions with enhanced precision and ultimately improving patient outcomes." - Michael Ebner (CEO and co-founder Hypervision Surgical)
The funding round was led by a syndicate of highly experienced European and American HealthTech investors, including HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures, the corporate venture arm of the optical systems multinational ZEISS Group - a global technology leader operating in the fields of optics and optoelectronics.
Syndicate of highly experienced European and American HealthTech investors
"Hypervision Surgical's hardware-agnostic solution has the potential to redefine the standard of care in surgical imaging across various procedures, from open to minimally invasive, robotics, and microscopic surgeries." - Raf Roelands (Investment Director HERAN Partners)
Daniel Dillinger, Investment Manager at Redalpine, emphasised:
“Hypervision Surgical’s objective tissue characterisation and analytics platform is uniquely positioned to drive surgical decision-making and address critical unmet needs in the growing field of minimally invasive surgery, which sees nearly 200 million procedures annually.” - Daniel Dillinger (Investment Manager Red Alpine)
Iñaki Berenguer, Founding Partner at LifeX Ventures, highlighted the potential impact:
"The innovation in AI-powered vision systems, with simplified deployment in hospitals, holds the key to significantly improving the lives of millions of patients undergoing critical surgeries. Hypervision Surgical has the necessary ingredients to lead in this category." - Iñaki Berenguer (Founding Partner LifeX Ventures)
Martin Frost (CBE, Founder of CMR Surgical) joins Board of Directors of Hypervision Surgical
In conjunction with the funding announcement, Hypervision Surgical is delighted to welcome Martin Frost CBE, Founder and former CEO of CMR Surgical, to its board of directors. Frost has an extensive track record as a technology executive and director, having spent decades building and leading multiple companies, including through initial public offerings. Notably, he founded CMR Surgical in 2014 and swiftly scaled it into a globally recognised unicorn in the field of surgical robotics. In recognition of his exceptional contributions to Robotics and the British Industry, Frost was honoured with a CBE (The Order of the British Empire).
"We are thrilled to have Martin Frost (CBE) join our board of directors. His unparalleled expertise in building and scaling surgical technology ventures will be invaluable as we navigate the next phase of Hypervision Surgical's growth and commercialisation efforts." - Michael Ebner (CEO and co-founderHypervision Surgical)
Secured funding to accelerate development and regulatory clearance of cutting-edge vision technology
The newly secured funding will accelerate the development of Hypervision Surgical's cutting-edge vision technology and will be used to secure regulatory clearance in the United States and Europe. The company will expand collaborations with leading surgeons, renowned surgical centres, and strategic industry partners on both sides of the Atlantic to ensure a successful market launch and smooth integration into clinical practice. Additionally, the completion of UK clinical evaluation studies on colorectal and neurosurgery in the coming year will further enhance its evidence base.
Read the full press release in Dutch
About
Hypervision Surgical Ltd a spin-out from King's College London, is developing an intraoperative imaging system that seamlessly integrates into the surgical workflow for real-time tissue characterisation. Their goal is to revolutionise surgical outcomes through advanced computer-assisted analysis, enhancing precision and patient safety.
Redalpine is the Swiss venture capital firm that empowers Game Changers. Founded in 2006, Redalpine brings together financial investment, operational expertise, and a vast international network to help ambitious entrepreneurs transform their vision into a reality. With over €1bn in assets under management and a disciplined, sector-agnostic investment strategy, the firm has backed some of Europe’s most disruptive companies, including N26, Taxfix, Inkitt, 9fin, Carvolution, Zenjob, vivenu,and Umiami. Redalpine has over 85 companies in its portfolio and invests Europe-wide from its offices in Zurich and Berlin.
LifeX Ventures is a New York-based venture capital firm investing in global visionary entrepreneurs using software and AIto develop transformational solutions that will extend the life of humans and the planet. With its $100M debut fund, LifeX is targeting the two largest sectors in the world: People (bio/health) and Planet (climate), where Software and AI suddenly matter.
ZEISS Ventures the corporate venture capital arm of the ZEISS Group, makes investments and actively manages a portfolio of startup companies. Their goal is to invest in and partner with deep-tech startups, which go beyond ZEISS' core business and have the potential to disrupt and innovate existing technologies and business models. ZEISS Ventures aims to provide startups not only with the capital they need, but also with access to its resources, capabilities, and global network as a deep-tech corporation in order to foster and accelerate their development.
